EDMONTON, Canada--(BUSINESS WIRE)--Canadian patients suffering from Restless Legs Syndrome (RLS) now have access to Relaxis®, the only medical device approved by the U.S. Food and Drug Administration for treating the symptoms of primary RLS, thanks to an exclusive new agreement between Sleep Therapeutics and Sensory NeuroStimulation Inc., maker of the Relaxis technology. Headquartered in Edmonton, with clinics located throughout Canada, Sleep Therapeutics has been helping Canadians sleep better since 2001. Relaxis is Health Canada Licensed and CSA certified.
“Providing RLS sufferers with a non-pharmaceutical solution to improve their sleep quality will enable our exceptional staff and company to help more people awaken their best lives,” said Lionel Marshall, CEO of Sleep Therapeutics. Marshall, who has over 20 years of industry experience, knows first-hand the effects of poor quality sleep; after optimizing treatment for his own sleep disorder, he experienced such a vast improvement in his life that he was motivated to start the company and help others experience better quality sleep.
About Restless Legs Syndrome and Relaxis
The U.S. National
Institute of Neurological Disorders and Stroke (NINDS) projects that an
estimated 12 million adults in North America may be suffering from RLS,
a life-long neurological condition that causes discomfort, pain and
sleep deprivation, particularly when individuals are resting. Many
patients find their only relief comes from physical movement, which
causes sleep interruption and leads to physical fatigue, impaired mental
functioning, and emotional stress. Although medication may be prescribed
to alleviate RLS suffering, some of these, including anti-convulsants,
narcotic opioids and muscle relaxants, present a risk of addiction or
interaction with other drugs patients may be taking.
Relaxis was designed by a doctor who was himself an RLS sufferer, and was granted commercial clearance by the U.S. Food and Drug Administration (FDA) in 2014 as the first and only prescription, noninvasive, non-medication alternative for improving quality of sleep in patients with primary Restless Leg Syndrome.
In September, Relaxis was introduced to Canadian medical professionals for the first time during the 7th Annual Conference of the Canadian Sleep Society in Toronto, Ontario. Canadian consumers will have their first opportunity to experience Relaxis by visiting Sleep Therapeutics’ exhibit booth at the National Women’s Show in Ottawa, October 24-25. Additional details about the Relaxis system, which is available on a prescription-only basis in Canada, are available at Sleep Therapeutics’ website, sleeptherapeutics.ca, or by visiting www.myrelaxis.com.
About Relaxis and Sensory NeuroStimulation Inc.
Based in San
Clemente, Calif., the privately held Sensory NeuroStimulation Inc. was
formed in 2009 after the company’s CEO, Fred Burbank, M.D., began
experiencing RLS and sought a non-medication solution to relieving the
condition’s symptoms. Sensory NeuroStimulation assembles Relaxis, the
first FDA-approved non-drug medical device that can improve the quality
of sleep in patients with primary Restless Legs Syndrome (RLS).
Additional information about the company and its technologies is
available at www.MyRelaxis.com.
About Sleep Therapeutics
Sleep Therapeutics’ mission is to
help our client’s transition from a life affected by sleep disorders, to
a healthy lifestyle of happiness and success. As sleep research
continues to evolve, the causes and serious effects of non-restorative
sleep are becoming more and more apparent. Reliable diagnostic tests and
treatments are vital to helping people attain the assistance they need
to awaken their best lives. Sleep Therapeutics has grown from their
first clinic in Nova Scotia to over 16 locations. Sleep Therapeutics
employs over 58 health and wellness personnel. We are most proud of our
exceptional staff and the genuine care they have for our clients and
their long-term well-being.
Relaxis is a registered trademark of Sensory NeuroStimulation Inc. All rights reserved.
SOURCES: “Restless Legs Syndrome Fact Sheet,” NIH/National Institute of Neurological Disorders and Stroke; “Restless Legs Syndrome,” www.mayoclinic.org; Clinical Data on file, Sensory NeuroStimulation Inc.
